SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Brandberg Yvonne) "

Sökning: WFRF:(Brandberg Yvonne)

  • Resultat 1-10 av 43
  • [1]2345Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Arver, Brita, et al. (författare)
  • Bilateral Prophylactic Mastectomy in Swedish Women at High Risk of Breast Cancer: A National Survey.
  • 2011
  • Ingår i: Annals of Surgery. - Lippincott Williams & Wilkins. - 1528-1140. ; 253:6, s. 1147-1154
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND/OBJECTIVE:: This study attempted a national inventory of all bilateral prophylactic mastectomies performed in Sweden between 1995 and 2005 in high-risk women without a previous breast malignancy. The primary aim was to investigate the breast cancer incidence after surgery. Secondary aims were to describe the preoperative risk assessment, operation techniques, complications, histopathological findings, and regional differences. METHODS:: Geneticists, oncologists and surgeons performing prophylactic breast surgery were asked to identify all women eligible for inclusion in their region. The medical records were reviewed in each region and the data were analyzed centrally. The BOADICEA risk assessment model was used to calculate the number of expected/prevented breast cancers during the follow-up period. RESULTS:: A total of 223 women operated on in 8 hospitals were identified. During a mean follow-up of 6.6 years, no primary breast cancer was observed compared with 12 expected cases. However, 1 woman succumbed 9 years post mastectomy to widespread adenocarcinoma of uncertain origin. Median age at operation was 40 years. A total of 58% were BRCA1/2 mutation carriers. All but 3 women underwent breast reconstruction, 208 with implants and 12 with autologous tissue. Four small, unifocal, invasive cancers and 4 ductal carcinoma in situ were found in the mastectomy specimens. The incidence of nonbreast related complications was low (3%). Implant loss due to infection/necrosis occurred in 21 women (10%) but a majority received a new implant later. In total, 64% of the women underwent at least 1unanticipated secondary operation. CONCLUSIONS:: Bilateral prophylactic mastectomy is safe and efficacious in reducing future breast cancer in asymptomatic women at high risk. Unanticipated reoperations are common. Given the small number of patients centralization seems justified.
  •  
2.
  • Bergenmar, Mia, et al. (författare)
  • Audio-recorded information to patients considering participation in cancer clinical trials - a randomized study
  • 2014
  • Ingår i: Acta Oncologica. - Taylor & Francis. - 1651-226X. ; 53:9, s. 1197-1204
  • Tidskriftsartikel (refereegranskat)abstract
    • Background. Patient information in cancer clinical trial is challenging. The value of audio-recording interventions for patients considering participating in clinical trials is unclear. The primary aim of this randomized study was to investigate effects of audio-recorded information on knowledge and understanding in patients considering participation in a clinical trial. Material and methods. Patients scheduled for information about a phases 2 or 3 trial by one of the 13 participating oncologists at the Department of Oncology during the study period (2008-2013) were eligible. The intervention consisted of an audio-recording on compact disc (CD) of the information at the medical consultation in which the patients were informed about a trial. Knowledge and understanding was measured by the questionnaire, Quality of Informed Consent. Results. A total of 130 patients were randomized, 70% of the calculated sample size (n = 186). Sixty-seven patients were randomized to the intervention. In total, 101 patients (78%) completed questionnaires. No statistical significant differences were found between the groups with respect to knowledge and understanding. The level of knowledge was relatively high, with the exceptions of the risks associated with, and the unproven nature of, the trial. Overall, patients who declined participation scored statistically significant lower on knowledge. Conclusion. The present study was underpowered and the results should therefore be interpreted with caution. Still, 130 patients were included with a response rate of 78%. A CD including the oral information about a clinical trial did not show any effects on knowledge or understanding. However, the levels of knowledge were high, possible due to the high levels of education in the study group. Information on risks associated with the trial is still an area for improvement.
  •  
3.
  • Brandberg, Yvonne, et al. (författare)
  • Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
  • 2013
  • Ingår i: Acta oncologica (Stockholm, Sweden). - 1651-226X. ; 52:6, s. 1086-1093
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose. To investigate the role of health-related quality of life (HRQoL) at randomization as independent prognostic factors for survival and time to failure, and to explore associations between HRQoL and treatment effects. Material and methods. In the Nordic adjuvant interferon trial, a randomized trial evaluating if adjuvant therapy with intermediate-dose IFN had the same beneficial effects on overall and disease-free survival in high-risk melanoma as high-dose IFN, 855 patients in Denmark, Finland, Norway, and Sweden were included. The EORTC QLQ-C30 questionnaire was used to assess HRQoL before randomization. Results. A total of 785 (92%) agreed to participate in the HRQoL-study and provided baseline HRQoL data. Prognostic variables included in the multivariate model were age, sex, performance status, tumor thickness, stage, and number of positive lymph nodes. Univariate analyses revealed an association between prolonged survival and age, stage/ number of metastatic lymph nodes and the HRQoL variable role functioning (p ≤ 0.01). After controlling for other prognostic factors, these variables remained independently statistically significant for survival. The univariate analyses of time to failure showed significant associations with the clinical variable stage/nodes and with the HRQoL variables physical functioning and role functioning. Adjusted multivariate analyses including the same clinical conditions as above showed statistically significant relationships between time to failure and global quality of life, physical functioning, role functioning, social functioning and fatigue (p ≤ 0.01). No interactions between HRQoL variables and treatment were found, with the exception for cognitive functioning. Conclusion. Role functioning was found to be an independent prognostic factor for time to failure and survival in patients with high-risk melanoma. Thus, also in this early stage of melanoma, HRQoL variables might be useful as important prognostic factors for time to failure and overall survival.
  •  
4.
  • Branstrom, Richard, et al. (författare)
  • Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma
  • 2012
  • Ingår i: European Journal of Cancer. - Elsevier. - 1879-0852. ; 48:16, s. 3052-3062
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Several melanoma susceptibility genes have been identified. As part of the international genetic research programme of the GenoMEL consortiums research on genetic mutations in melanoma families, the aim of this study was to examine family members' views about their risk of melanoma, gene testing and genetic research. Methods: Self-report data were gathered using online and paper-based surveys available in four languages among 312 individuals (62% from Europe, 18% from Australia, 13% from the United States of America (USA) and 7% from Israel). Results: Fifty three percent had been diagnosed with a melanoma, and 12% had a positive susceptibility gene test result. Respondents with many moles and freckles were more likely to perceive themselves at risk for developing melanoma (odds ratio [OR](Freckles) = 2.24 with 95% confidence interval [CI] = 1.18-4.26; ORMany (moles) = 6.92, 95% CI = 2.37-20.23). Respondents who had received a non-informative (negative) genetic test result were much less likely to perceive themselves at increased risk (OR = 0.17, 95% CI = 0.04-0.73). Safe-guards were perceived as important to protect genetic information, but there was also support for the storage and exchange of such information. Overall, respondents were in favour of genetic testing, even if current knowledge about melanoma risk genes is still limited. Contrary to previous studies, participants reported that a non-informative (negative) genetic test result, although not necessarily indicative of lower risk of melanoma, would be likely to reduce their practise of preventive behaviours. Conclusions: Participants were influenced by their phenotype and test results in risk estimations. They expressed positive views on genetic research and towards genetic testing, but reported that a non-informative (negative) test result might be associated with an (erroneous) perception of reduced risk and fewer preventive behaviours. These results highlight the urgency of improving the quality of genetic counselling and increasing the effectiveness of communication regarding genetic test results. (C) 2012 Elsevier Ltd. All rights reserved.
  •  
5.
  • Browall, Maria, et al. (författare)
  • A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment
  • 2017
  • Ingår i: Supportive Care in Cancer. - Springer. - 0941-4355 .- 1433-7339. ; 25:5, s. 1423-1429
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Purpose</p><p>The aim was to prospectively map symptom clusters in patients with stage I–IIIa breast cancer during standard chemotherapy treatment in a randomised study.</p><p>Methods</p><p>Participants completed the Memorial Symptom Assessment Scale (MSAS) at baseline, day 12 after the first and third cycle of FEC 75 or FEC 100, and day 12 after the last cycle of Taxotere. Cut-off values for symptom scores, a mean value based on each individual reporting a symptom including occurrence, frequency, severity and distress for inclusion in analysis, were determined.</p><p>Results</p><p>The symptom burden cluster analysis was conducted in two steps and included symptoms with high frequency and high levels of distress. The factor analysis revealed three symptom clusters; physical, gastro (phys/gastro) and emotional, with core symptoms that remained stable over time. The most prevalent symptoms for the total sample during all cycles were as follows: lack of energy (range between 48 and 90%), feeling sad (48–79%), difficulty sleeping (54–78%), difficulty concentrating (53–74%), worrying (54–74%) and pain (29–67%).</p><p>Conclusion</p><p>In summary, we have prospectively established that symptom clusters remain stable over time with a basis of core symptoms. This knowledge will aid in the development of effective core symptom-focused interventions to minimise symptom burden for patients treated with chemotherapy for breast cancer.</p>
  •  
6.
  • Browall, Maria, et al. (författare)
  • A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment
  • 2017
  • Ingår i: Supportive Care in Cancer. - Springer. - 0941-4355 .- 1433-7339. ; 25:5, s. 1423-1429
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Purpose</p><p>The aim was to prospectively map symptom clusters in patients with stage I–IIIa breast cancer during standard chemotherapy treatment in a randomised study.</p><p>Methods</p><p>Participants completed the Memorial Symptom Assessment Scale (MSAS) at baseline, day 12 after the first and third cycle of FEC 75 or FEC 100, and day 12 after the last cycle of Taxotere. Cut-off values for symptom scores, a mean value based on each individual reporting a symptom including occurrence, frequency, severity and distress for inclusion in analysis, were determined.</p><p>Results</p><p>The symptom burden cluster analysis was conducted in two steps and included symptoms with high frequency and high levels of distress. The factor analysis revealed three symptom clusters; physical, gastro (phys/gastro) and emotional, with core symptoms that remained stable over time. The most prevalent symptoms for the total sample during all cycles were as follows: lack of energy (range between 48 and 90%), feeling sad (48–79%), difficulty sleeping (54–78%), difficulty concentrating (53–74%), worrying (54–74%) and pain (29–67%).</p><p>Conclusion</p><p>In summary, we have prospectively established that symptom clusters remain stable over time with a basis of core symptoms. This knowledge will aid in the development of effective core symptom-focused interventions to minimise symptom burden for patients treated with chemotherapy for breast cancer.</p>
  •  
7.
  • Cortés-González, Jeff R, et al. (författare)
  • Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy
  • 2013
  • Ingår i: International journal of oncology. - 1791-2423. ; 42:1, s. 109-117
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to investigate the role of 70 Gy salvage radiotherapy (SRT) combined with short-term neoadjuvant hormonal therapy (NHT) in the treatment of recurrent disease after radical prostatectomy (RP), and to consider quality of life (QoL), survival outcomes and impact of co-morbidities on treatment-related rectal-genitourinary toxicity. Electronic records of 184 SRT patients treated consecutively between October 2001 and February 2007 were analyzed. Median age was 64 years (median follow-up 48 months). NHT was given to 165 patients (median 3 months). Pre-RP and pre-SRT PSA, PSA doubling time, Gleason score (GS), seminal vesicle invasion (SVI) and detectable post-SRT PSA were recorded. Any detectable PSA or PSA >0.1 ng/ml + nadir was considered biochemical failure (BcF). The Charlson co-morbidity index was used to correlate co-morbidities and rectal-genitourinary toxicity. Scores from the health-related QoL EORTC QLQ-C30 and PR-25 questionnaires were also evaluated. In 116 (63%) patients, a long-lasting curative effect was indicated by undetectable PSA levels. In univariate analysis, using BcF as an outcome variable, p 1.0 ng/ml and 80/134 (60%) patients with PSA doubling time (PSADT) 50% of patients with recurrence after RP with acceptable rectal-genitourinary toxicity and without negatively affecting long-term QoL. Non-metastatic patients should not be disqualified from receiving SRT although presenting with poor prognostic factors at surgery.
  •  
8.
  • Foukakis, Theodoros, et al. (författare)
  • Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer : A randomized clinical trial
  • 2016
  • Ingår i: JAMA: The Journal of the American Medical Association. - American Medical Association. - 0098-7484. ; 316:18, s. 1888-1896
  • Tidskriftsartikel (refereegranskat)abstract
    • IMPORTANCE Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy.Whether tailored dosing can improve outcomes is unknown, as is the role of dose-dense adjuvant chemotherapy. OBJECTIVE To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes of early breast cancer compared with a standard 3-weekly chemotherapy schedule. DESIGN, SETTING, AND PARTICIPANTS A randomized, open-label, phase 3 trial ofwomen aged 65 years and younger who had surgery for nonmetastatic node-positive or high-risk node-negative breast cancer at 86 sites in Sweden, Germany, and Austria between February 20, 2007, and September 14, 2011. INTERVENTIONS Patients were randomized 1:1 either to 4 cycles of leukocyte nadir-based tailored and dose-dense adjuvant epirubicin and cyclophosphamide every 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks, or to standard-interval chemotherapy with 3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3 cycles of docetaxel every 3 weeks. MAIN OUTCOMES AND MEASURES The primary end pointwas breast cancer recurrence-free survival (BCRFS). Secondary end points included 5-year event-free survival (EFS), distant disease-free survival (DDFS), overall survival (OS), and rates of grade 3 or 4 toxic effects. RESULTS Among 2017 randomized patients (1006 in the tailored dose-dense group and 1011 in the control group; median [IQR] age, 51 [45-58] years; 80% with hormone receptor-positive tumors; 97%with node-positive disease), 2000 received study treatment (1 cycle of chemotherapy; 1001 in the tailored dose-dense group and 999 in the control group). After a median follow-up of 5.3 years (IQR, 4.5-6.1 years), 269 BCRFS events were reported, 118 in the tailored dose-dense group and 151 in the control group (HR, 0.79; 95%CI, 0.61-1.01; log-rank P =.06; 5-year BCRFS, 88.7%vs 85.0%). The tailored dose-dense group had significantly better EFS than the control group (HR, 0.79; 95%CI, 0.63-0.99; P =.04; 5-year EFS, 86.7%vs 82.1%). The groups did not differ in OS (HR, 0.77; 95%CI, 0.57-1.05; P =.09; 5-year OS, 92.1% vs 90.2%) or DDFS (HR, 0.83; 95%CI, 0.64-1.08; P =.17; 5-year DDFS, 89.4%vs 86.7%). Grade 3 or 4 nonhematologic toxic effects occurred in 527 (52.6%) in the tailored dose-dense group and 366 (36.6%) in the control group. CONCLUSIONS AND RELEVANCE Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival. Nonhematologic toxic effects were more frequent in the tailored dose-dense group. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00798070; isrctn.org Identifier: ISRCTN39017665.
  •  
9.
  •  
10.
  • Lennernäs, Bo, 1963-, et al. (författare)
  • Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes.
  • 2015
  • Ingår i: Acta oncologica (Stockholm, Sweden). - 1651-226X. ; 54:6, s. 875-881
  • Tidskriftsartikel (refereegranskat)abstract
    • Background. Treatment of localized prostate cancer (PC) is controversial. This is the first randomized study comparing an open surgery procedure (radical prostatectomy) with a combination of high-dose rate brachytherapy (2 × 10 Gy) and external beam radiotherapy (25 × 2 Gy) in PC patients in Sweden 1996-2001. The two randomization arms were compared regarding differences in patients-reported outcomes, such as complications and health-related quality of life (HRQoL). Material and methods. The patients had localized/locally advanced PC, clinical category T1b-T3a, N0, M0 and PSA ≤ 50 ng/ml. All underwent total androgen blockade (six months). Self-reported HRQoL and symptoms including urinary, bowel, and sexual side effects were investigated prospectively before randomization and 12 and 24 months after randomization. A total of 89 patients were randomized and completed the EORTC QLQ C-33 and EORTC PR-25 questionnaires. Results. Over the study period, there were no discernible differences in HRQoL, or complications between the two groups. Emotional functioning, however, improved statistically significantly over time, whereas Social functioning decreased, and financial difficulties increased. No statistically significant differences in group-by-time interactions were found. The survival rate was 76%. Only eight patients (9%) died of PC. Conclusion. Open radical prostatectomy and the combined high-dose rate brachytherapy with external beam radiation appeared to be comparable in the measured outcomes. It was not possible to draw any conclusion on the efficacy of the two treatments due to insufficient power of the study.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 43
  • [1]2345Nästa
Åtkomst
fritt online (5)
Typ av publikation
tidskriftsartikel (42)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (38)
övrigt vetenskapligt (5)
Författare/redaktör
Brandberg, Yvonne (42)
Johansson, Hemming (18)
Brandberg, Y, (15)
Hatschek, Thomas (8)
Johansson, H (6)
Loman, Niklas, (6)
visa fler...
Glimelius, Bengt, (5)
Wickman, Marie (5)
Nilsson, Sten, (5)
Carlsson, Lena, (5)
Bergh, Jonas (5)
Arver, Brita (5)
Sandelin, Kerstin (5)
Foukakis, Theodoros (5)
Ringberg, Anita (4)
HATSCHEK, T (4)
Juliusson, Gunnar, (4)
Henriksson, Karin (4)
Hellborg, Henrik (4)
Karlsson, Per (4)
Lindman, Henrik, (4)
Lundberg, Jonas, (4)
Bergkvist, Leif, (4)
Ehrencrona, Hans, (4)
Liliemark, Jan, (4)
Isaksson, Karin (4)
Atterhem, Hans (4)
Baan, Annika (4)
Emanuelsson, Monica (4)
Arving, Cecilia, (4)
Karlsson, Karin, (4)
Bergh, Jonas C. S. (4)
Bjohle, Judith (4)
Bosch, Ana (4)
Einbeigi, Zakaria (4)
Fredholm, Hanna (4)
Isaksson-Friman, Eri ... (4)
Elinder, Ellinor (4)
Lekberg, Tobias (4)
Wallvik, Jonas (4)
Isacsson, Ulf, (3)
Lennernäs, Bo, 1963- ... (3)
Svensson, H (3)
Loman, N (3)
Einbeigi, Zakaria, 1 ... (3)
Askmalm, Marie Stenm ... (3)
Hellstrom, Mats (3)
Einbeigi, Z. (3)
Uggla, Bertil (3)
Svensson, Helene, (3)
visa färre...
Lärosäte
Karolinska Institutet (15)
Uppsala universitet (10)
Göteborgs universitet (8)
Lunds universitet (8)
Umeå universitet (5)
Linköpings universitet (5)
visa fler...
Örebro universitet (4)
Chalmers tekniska högskola (2)
Högskolan i Jönköping (1)
Högskolan i Skövde (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (42)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (42)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy